Research programme: anti-phosphatidylserine monoclonal antibodies - Affitech/Avid Bioservices
Alternative Names: 11.31; 1N11; 3J05; AT 004; AT 005; Fully human bavituximab; PGN 632; PGN 634; PGN 635Latest Information Update: 28 Apr 2018
At a glance
- Originator Affitech A/S; Peregrine Pharmaceuticals
- Developer Affitech A/S; Avid Bioservices; Peregrine Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Phosphatidylserine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Cancer; HIV infections; Lassa fever; Viral haemorrhagic fevers; Viral infections; Yersinia infections
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in HIV-infections in USA (Parenteral)
- 21 Apr 2018 Parmacodynamics data from preclinical trial in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
- 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices